ISG12a and its interaction partner NR4A1 are involved in TRAIL-induced apoptosis in hepatoma cells
Related Experiment Video
Updated: Jan 28, 2026

Identification of Protein Interaction Partners in Mammalian Cells Using SILAC-immunoprecipitation Quantitative Proteomics
Published on: July 6, 2014
Nianli Liu1,2, Zhiyuan Wu1,2, Aoxing Chen1,2
1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in cancer cells while sparing normal cells, thereby leading to the development of TRAIL receptor agonists for cancer treatment. However, these agonist-based therapeutics exhibit little clinical benefits due to the lack of biomarkers to predict whether patients are responsive to the treatment, as well as determine the resistance of cancer cells to TRAIL-based agonists. Our previous study has demonstrated that ISG12a enhances TRAIL-induced apoptosis and might serve as a biomarker to predict the TRAIL response. The downstream mechanism by which ISG12a augments TRAIL-induced apoptosis remains to be elucidated. In this study, we found that ISG12a was localized in the mitochondria and nucleus and augmented TRAIL-induced apoptosis through intrinsic apoptotic pathway. In addition, ISG12a interacted with NR4A1 and promoted its nuclear-to-cytoplasm translocation. Upon translocate to cytoplasm, NR4A1 targeted mitochondria and induced Bcl2 conformational change, thereby exposing its BH3 domain. Moreover, TRAIL treatment can induce NR4A1 expression through the activation of NF-κB in TRAIL-resistant Huh7 hepatoma cells. Knockdown of NR4A1 could overcome TRAIL resistance. However, in TRAIL-sensitive LH86 liver cancer cells, TRAIL activated the Jun N-terminal kinases signalling pathway. Overall, these results showed that both ISG12a and its interaction partner NR4A1 are involved in TRAIL-mediated apoptosis in hepatoma cells.
Insights
ISG12a enhances cancer cell death induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). This protein interacts with NR4A1, promoting apoptosis and potentially overcoming TRAIL resistance in cancer treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Death Mechanisms
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy by selectively inducing apoptosis in cancer cells.
- Clinical applications of TRAIL agonists are limited by a lack of predictive biomarkers for patient response and mechanisms of cancer cell resistance.
- Previous research identified ISG12a as a potential biomarker that enhances TRAIL-induced apoptosis.
Purpose of the Study:
- To elucidate the downstream mechanism by which ISG12a augments TRAIL-induced apoptosis.
- To investigate the interaction between ISG12a and its downstream partners in the context of TRAIL signaling.
- To explore the role of ISG12a and its interacting proteins in mediating TRAIL sensitivity and resistance in hepatoma cells.
Main Methods:
- Subcellular localization studies of ISG12a.
- Analysis of the intrinsic apoptotic pathway activation.
- Co-immunoprecipitation to identify interacting proteins.
- NR4A1 translocation assays and functional studies.
- NF-κB and Jun N-terminal kinase signaling pathway analysis.
- Gene knockdown experiments to assess functional significance.
Main Results:
- ISG12a localizes to mitochondria and the nucleus, enhancing TRAIL-induced apoptosis via the intrinsic pathway.
- ISG12a interacts with NR4A1, promoting its translocation from the nucleus to the cytoplasm.
- Cytoplasmic NR4A1 targets mitochondria, induces Bcl2 conformational changes, and exposes the BH3 domain.
- TRAIL induces NR4A1 expression via NF-κB activation in TRAIL-resistant cells, and NR4A1 knockdown overcomes this resistance.
- TRAIL activates Jun N-terminal kinases in TRAIL-sensitive cells.
Conclusions:
- ISG12a and NR4A1 are key mediators of TRAIL-induced apoptosis in hepatoma cells.
- The ISG12a-NR4A1 interaction and subsequent NR4A1 cytoplasmic translocation are critical for augmenting TRAIL sensitivity.
- Understanding these mechanisms provides insights into overcoming TRAIL resistance and developing targeted cancer therapies.
Related Concept Videos
Apoptosis
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Overview of Cell-Matrix Interactions
piRNA - Piwi-interacting RNAs

